Prostate cancer screening: And yet it moves! - Abstract

The debate of prostate cancer (PCa) screening has been shaped over decades.

There is a plethora of articles in the literature supporting as well as declining prostate-specific antigen (PSA) screening. Does screening decrease PCa mortality? With the long-term results of the European Randomized Study of Screening for Prostate (ERSPC) the answer is clearly YES. It moves! However, in medicine there are no benefits without any harm and thus, screening has to be performed in targeted and smart way-or in other words-in a risk-adapted fashion when compared with the way it was done in the past. Here, we discuss the main findings of the ERSPC trials and provide insights on how the future screening strategies should be implemented.

Written by:
Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F.   Are you the author?
Department of Urology, Cantonal Hospital Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Germany.

Reference: Asian J Androl. 2014 Dec 12. Epub ahead of print.
doi: 10.4103/1008-682X.143310


PubMed Abstract
PMID: 25532573

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe